← Back to scans

When will Anduril IPO? — Before Jun 1, 2027

KXIPOANDURIL-27JUN01 · Economics · 2026-04-10
15%
Agent
17%
Market Price
-2.0%
Edge
68%
Confidence
Volume: 17,564
Spread: 3.0c
Days to resolution: 417
Markets in event: 17
Final Rationale
My independent estimate of 22% contained a logical flaw correctly identified by the Devil's Advocate: the combined probability exceeded the binding constraint sub-question (sq1: 18% probability of filing/confirmation), which is impossible since filing is a necessary precondition for resolution. I ACCEPT this critique and adjust downward. I also ACCEPT Challenge 5 — Palmer Luckey's general IPO statements deserve near-zero weight given the contradictory action of raising $4B privately in March 2026, which eliminates IPO financial necessity for 2+ years. The market at 14% reflects a dramatic repricing from ~71% to 14% following the March 2026 mega-round, and with HIGH orderbook depth (8,329), this is a well-informed signal. My adjusted estimate of ~15% sits between the corrected binding constraint (18%) and the market (14%), reflecting that while an IPO is unlikely given the fresh $4B in capital and explicit leadership signals about patience, there remains a small but real chance of a confidential S-1 filing or surprise acceleration driven by investor liquidity pressure or IPO ratchet provisions we don't know about.
Price vs. prediction
How the market moved after the agent's call. Solid blue line is the actual market price; dashed line is the agent's static forecast at $t{=}0$.
$n = 54$ follow-ups
1. Planner Opus · Fermi decomposition + tool plan
Tools chosen: kalshi_data kalshi_orderbook article_search web_search earnings_data wikipedia_lookup code_execution
Sub-questions (Fermi decomposition)
  1. Will Anduril file an S-1 or publicly confirm IPO plans before June 1, 2027? (w=0.35)
  2. Is Anduril's current financial position and business trajectory consistent with IPO readiness within 14 months? (w=0.25)
  3. Will IPO market conditions remain favorable enough to support a large defense tech IPO before June 1, 2027? (w=0.20)
  4. Has Anduril leadership publicly signaled intent to IPO within the next 1-2 years as of early 2026? (w=0.20)
Planner reasoning
This question asks whether Anduril Industries will confirm an IPO before June 1, 2027 — approximately 14 months away. Key analytical dimensions: (1) Reference class: Defense tech unicorns that raised large rounds at high valuations (Palantir took 17 years; Shield AI, Joby, others stayed private longer than expected). Anduril raised at $14B in 2024, which typically suppresses near-term IPO urgency. (2) Causal mechanisms: Palmer Luckey has historically expressed skepticism about public markets for defense companies due to shareholder activism concerns on defense contracts. However, accelerating revenue growth, Pentagon budget shifts, or investor liquidity pressure could force the timeline. (3) Temporal dynamics: For YES, Anduril would need to hire underwriters and file S-1 by roughly December 2026 (only 8 months away), allowing 3-6 months for SEC review and roadshow before June 2027. If no S-1 preparation signals exist in April 2026, the window is very tight. (4) The question requires only confirmation of IPO plans, not completion — a formal announcement could count even if the IPO date extends past June 2027. This broadens the YES outcome somewhat. Key differentiator from generic IPO questions: defense companies have unique considerations around government contract disclosures, classified programs, and political exposure that make public markets less attractive than for consumer tech. Prediction market pricing will be critical signal.
2. Research Parallel tool calls · legacy v2
ToolStatusTimeItemsSummary
kalshi_data OK 2.1s -
kalshi_orderbook OK 0.3s -
article_search OK 1.0s -
web_search OK 50.8s -
earnings_data FAILED 0.9s -
wikipedia_lookup OK 1.3s -
code_execution OK 0.0s -
Errors: earnings_data: None
3. Evidence Synthesis Sonnet · 16 items · legacy v2
#StrengthCredibilityDirectionSourceClaimPriced In
1 STRONG 78 ↓ DOWN kalshi_data The Kalshi prediction market currently prices Anduril IPO before June 1, 2027 at 14%, down 22% over the past 30 days from a high of 71%. Yes
2 MODERATE 72 NEUTRAL kalshi_orderbook The orderbook shows HIGH liquidity with 8,329 depth, giving this market signal meaningful reliability despite the wide spread. Yes
3 STRONG 85 ↓ DOWN web_search Anduril has not filed an S-1 and does not trade publicly; no formal IPO filing or confirmation has been made as of early April 2026. Yes
4 MODERATE 65 ↓ DOWN web_search A reported March 2026 funding round raising ~$4 billion at a ~$60 billion valuation likely pushes IPO timeline back to at least 2027, according to analysts cited in the web search summary. No
5 MODERATE 50 NEUTRAL code_execution Timeline analysis shows the latest plausible S-1 filing date for a pre-June 2027 IPO is around March 3, 2027, giving roughly 327 days from now; a rough base rate for a unicorn IPO in a 14-month window is estimated at ~20%. No
6 STRONG 62 ↑ UP web_search Anduril's revenue is estimated to have grown from ~$1B in 2024 to ~$2B in 2025, with projections of ~$4B in 2026, demonstrating strong hypergrowth consistent with IPO readiness metrics. Yes
7 STRONG 70 ↓ DOWN web_search Anduril's valuation has reportedly grown to $60-70 billion as of early 2026 following a $4B fundraising round led by a16z and Thrive Capital, suggesting continued private capital availability and reduced urgency to IPO. No
8 MODERATE 80 ↑ UP article_search Anduril's Fury CCA unmanned jet completed its first test flight in October 2025, and Arsenal-1 manufacturing facility is expected to begin production in July 2026, indicating product maturity milestones are progressing. Yes
9 STRONG 75 ↓ DOWN web_search Trae Stephens (Anduril board member) told CNBC the company isn't on a 'rapid path' to an IPO, signaling internal preference to remain private longer. Yes
10 MODERATE 65 ↓ DOWN web_search Anduril leadership indicated the company wants to demonstrate profitability and prove out Arsenal-1 operations before listing, suggesting the IPO is contingent on operational milestones not yet achieved. Yes
11 MODERATE 75 ↑ UP article_search The U.S. IPO market showed strong activity in mid-2025, with Circle, Chime, eToro, and Hinge Health all successfully going public above expected ranges, indicating a favorable IPO environment. Yes
12 MODERATE 68 NEUTRAL article_search IPO market analysts in mid-2025 described conditions as 'a return to normalcy' rather than a boom, suggesting moderate rather than exceptional conditions for large-cap IPOs. Yes
13 WEAK 60 ↓ DOWN article_search A partial U.S. government shutdown occurred in late January 2026, adding political and fiscal uncertainty that could affect defense contract visibility and IPO market confidence. Yes
14 STRONG 72 ↑ UP web_search Palmer Luckey has publicly confirmed Anduril will 'definitely' be a publicly traded company and cited 2026 as a possible IPO year, specifically arguing public status is necessary to compete for trillion-dollar defense contracts. Yes
15 MODERATE 65 ↓ DOWN web_search Despite Luckey's general IPO intent signals, no specific timeline has been set, and the March 2026 fundraising round is interpreted by analysts as pushing the IPO to at least 2027. No
16 MODERATE 68 ↓ DOWN article_search Palmer Luckey has historically expressed concern about public market shareholders objecting to defense contracts, which acts as a structural deterrent to early IPO despite business readiness. Yes
Information Gaps
  • No confirmed data on whether Anduril has hired investment banks or begun S-1 preparation as of April 2026 — the most direct leading indicator of near-term IPO.
  • No audited financial statements or confirmed profitability data; revenue figures are analyst estimates, not verified filings.
  • No data on the specific terms or structure of the March 2026 fundraising round (e.g., liquidation preferences, IPO ratchets) that could create or remove IPO pressure.
  • No information on whether Anduril's Arsenal-1 facility has reached operational milestones that Luckey identified as a precondition for IPO.
  • No data on current IPO market conditions as of April 2026 (articles only go through early 2026); unclear whether the mid-2025 IPO window has continued.
  • No data on SEC confidential filing (S-1 draft) activity, which would not be public but could be leaked.
  • No information on investor lock-up structures or early investor liquidity demands that could pressure an IPO timeline.
Key Uncertainties
  • Whether the March 2026 $4B fundraising round definitively pushes the IPO beyond June 2027 — large private rounds typically reduce urgency but may have IPO timeline covenants.
  • Whether Anduril's Arsenal-1 facility operational timeline (July 2026 production start) could catalyze or delay IPO preparations.
  • Palmer Luckey's actual private decision-making vs. public signals — he has given mixed signals (general intent to IPO vs. no rapid path).
  • The durability of U.S. IPO market conditions through late 2026/early 2027 given ongoing political uncertainty (government shutdowns, tariff policy).
  • Whether classified program disclosures required for an S-1 represent an insurmountable barrier for defense-specific IPO timing.
  • Whether the 30-day -22% drop in Kalshi market price reflects new information (March 2026 fundraising news) or general sentiment shift.
Market Context
Price: 0.14 · 7d: -0.01 · 30d: -0.22
Volume: MODERATE — 418 avg daily contracts, active enough to be meaningful · Depth: HIGH — 8,329 depth with high liquidity designation
Reliability: MEDIUM-HIGH — substantial liquidity and depth, but the dramatic 30-day price drop from 71% to 14% suggests the market is repricing on new information (likely the March 2026 fundraising round), making the current 14% a more informed signal than the prior range suggests
4. Independent Forecaster Opus · No market price · legacy v2 Did NOT see market price
Independent estimate: 22% (62% confidence)
base rate
22%
62% conf
evidence driven
22%
62% conf
contrarian
22%
62% conf
Spread
0pp
Low disagreement
sq1: Will Anduril file an S-1 or publicly confirm IPO plans before June 1, 2027?
18%
Base rate: For a late-stage unicorn valued at $60B+ that just raised $4B in private capital (March 2026), the probability of filing an S-1 within 14 months is low. Historical reference class: companies that raise mega-rounds typically wait 18-36 months before IPO. Palantir waited years after its last private round. The $4B raise at $60B valuation (STRONG DOWN, ~-8%) strongly suggests no imminent IPO pressure. No S-1 has been filed and no underwriter selection has been reported (STRONG DOWN, ~-5% from a 20% base). Palmer Luckey's general statements about eventually going public provide a small upward push (+2%), but Trae Stephens' 'not on a rapid path' comment pushes back down. The question asks about 'confirmation' which is broader than actual filing — a formal announcement could count — which pushes up slightly (+3%). Starting from ~20% base rate, net adjustments bring this to ~18%.
sq2: Is Anduril's current financial position and business trajectory consistent with IPO readiness within 14 months?
55%
Revenue trajectory is impressive: ~$1B (2024) → ~$2B (2025) → projected ~$4B (2026). This hypergrowth is consistent with companies that successfully IPO. Product milestones (Fury test flight, Arsenal-1) are progressing. STRONG UP (+15% from neutral 50%). However, leadership explicitly stated they want to demonstrate profitability and prove Arsenal-1 operations first (STRONG DOWN, -8%). Arsenal-1 production starts July 2026 — proving it out would take at least 6+ months, pushing past June 2027 deadline. The company is financially ready in terms of scale but may not meet its own self-imposed operational milestones. Net: ~55% — the business could support an IPO, but internal readiness criteria may not be met.
sq3: Will IPO market conditions remain favorable enough to support a large defense tech IPO before June 1, 2027?
60%
Base rate: IPO markets are open roughly 60-70% of the time for large-cap, high-growth companies. Mid-2025 showed strong IPO activity (Circle, Chime, eToro). The 'return to normalcy' framing suggests sustainable rather than bubble conditions. Government shutdown in Jan 2026 is a minor negative (WEAK DOWN, -2%). Defense sector is politically favorable under current administration. Key uncertainty: macroeconomic conditions in late 2026/early 2027 are unknown. Starting from ~65% base, small downward adjustments for political uncertainty and information gaps bring this to ~60%.
sq4: Has Anduril leadership publicly signaled intent to IPO within the next 1-2 years as of early 2026?
35%
Palmer Luckey has said Anduril will 'definitely' go public and cited 2026 as a possible year (STRONG UP, +15% from a 25% base). However, the March 2026 $4B raise is widely interpreted as pushing the timeline to at least 2027 (MODERATE DOWN, -5%). Trae Stephens said 'not on a rapid path' (MODERATE DOWN, -3%). Luckey's concerns about shareholder activism on defense contracts create structural hesitation (MODERATE DOWN, -2%). The signals are mixed: general long-term intent is clear, but specific near-term (pre-June 2027) commitment is absent. The massive private round essentially serves as a counter-signal. Net: ~35%.
Show full reasoning trace
base rate: For late-stage unicorns valued at $60B+ that recently completed major private funding rounds, the base rate of IPO within 14 months is roughly 15-25%. Historical precedents: Palantir waited years after peak private valuations; SpaceX has remained private indefinitely; Stripe delayed for years after large private rounds. Defense tech adds unique complications (classified programs, political exposure). The March 2026 $4B raise is the strongest signal against near-term IPO.
evidence updates: March 2026 $4B raise at $60B valuation: STRONG DOWN (-8-10%). No S-1 filed or underwriters hired: STRONG DOWN (-5%). Palmer Luckey's general IPO intent: MODERATE UP (+5%). Revenue hypergrowth to ~$4B: MODERATE UP (+5%). Trae Stephens 'not rapid path': MODERATE DOWN (-3%). Arsenal-1 production not yet proven: MODERATE DOWN (-3%). Favorable IPO market conditions: WEAK UP (+2%).
combination method: Weighted average of sub-questions with adjustment toward the binding constraint (sq1: actual filing/confirmation). The enabling conditions (financial readiness, market conditions, leadership signals) are necessary but not sufficient — the actual decision to file is what matters for resolution.
final: The convergence of evidence points to ~22% probability. The strongest factor is the March 2026 mega-round, which historically delays IPOs by 18-36 months. While Anduril's business fundamentals are IPO-ready, leadership has explicitly signaled patience. The question's broader resolution criteria (confirmation, not just completion) provides some upside, but even confirmation would require active preparation beginning within months. The 14-month window from April 2026 to June 2027 is tight given the fresh capital injection.
ensemble: {'ensemble_count': 3, 'perspectives': {'base_rate': {'p_yes': 0.22, 'confidence': 0.62}, 'evidence_driven': {'p_yes': 0.22, 'confidence': 0.62}, 'contrarian': {'p_yes': 0.22, 'confidence': 0.62}}, 'spread': 0.0, 'individual_p_yes': {'base_rate': 0.22, 'evidence_driven': 0.22, 'contrarian': 0.22}}
5. Devil's Advocate Sonnet · legacy v2 Market price revealed
Math Error Reasoning Flaw Overconfidence
Challenges
  1. The ensemble shows zero spread across all three perspectives (base_rate, evidence_driven, contrarian all at exactly 0.22). This is a red flag — a genuine contrarian perspective should diverge meaningfully. The 'contrarian' lens should consider scenarios like: Anduril's $4B round includes IPO ratchets or investor liquidity pressure that could accelerate an IPO, or that the company files a confidential S-1 without public knowledge. The lack of any spread suggests the ensemble is not genuinely stress-testing the forecast.
  2. The combination method claims to weight toward the 'binding constraint' (sq1: filing/confirmation at 18%), but the final estimate of 22% is actually ABOVE this binding constraint. If sq1 is truly the gating factor, the combined probability should be at or below 18%, not above it. This is a mild math/logic error — you cannot have a higher probability of IPO than the probability of the necessary precondition (filing/confirmation).
  3. The sub-question on financial readiness (sq2: 55%) and market conditions (sq3: 60%) are interesting context but arguably irrelevant to the final probability if the company has explicitly signaled it won't IPO soon. The forecaster acknowledges these are 'necessary but not sufficient' but then lets them pull the estimate above the binding constraint anyway.
  4. The 30-day market drop from ~36% (implied from 14% + 22% drop) to 14% is significant new information. The forecaster notes the March 2026 fundraising round as the likely cause but may be underweighting how definitively this round signals against a near-term IPO. A $4B raise at $60B is not just 'pushing the timeline' — it's actively providing the exact capital and runway that eliminates IPO necessity for 2+ years.
  5. The forecaster gives Palmer Luckey's general statements about eventually going public a MODERATE UP (+5%) adjustment, but these statements are years old and have been superseded by the March 2026 fundraising action. Actions (raising $4B privately) speak louder than words (general intent to eventually IPO). The verbal signals should receive near-zero weight given the contradictory action.
  6. The information gap about IPO ratchets and investor liquidity demands is correctly identified but not incorporated into the estimate. If the $4B round included standard late-stage terms (which often include IPO forcing mechanisms after 2-3 years, not 14 months), this would actually reinforce the DOWN case rather than create ambiguity.
Suggested adjustment: -4pp
The combined forecast of 22% exceeds the binding constraint sub-question (sq1: 18% for filing/confirmation), which is logically inconsistent. The final probability should be at or below the probability of the necessary precondition. Additionally, Palmer Luckey's general IPO intent statements deserve less weight given the contradictory March 2026 mega-round. Adjusting down to ~18% to align with the binding constraint logic the forecaster themselves identified.
Market comparison: Forecaster: 22%, Market: 14%. The 8-point divergence is modest and both estimates are in the same general range. The market's 14% may be slightly more informed given the dramatic repricing following the March 2026 fundraising news. The forecaster's estimate should come down to ~18% based on internal logic errors (binding constraint violation), which narrows the gap. The remaining ~4% divergence is within reasonable disagreement range and doesn't require further market-driven adjustment.
6. Aggregator Opus · final calibrated forecast
15% (68% confidence)
My independent estimate of 22% contained a logical flaw correctly identified by the Devil's Advocate: the combined probability exceeded the binding constraint sub-question (sq1: 18% probability of filing/confirmation), which is impossible since filing is a necessary precondition for resolution. I ACCEPT this critique and adjust downward. I also ACCEPT Challenge 5 — Palmer Luckey's general IPO statements deserve near-zero weight given the contradictory action of raising $4B privately in March 2026, which eliminates IPO financial necessity for 2+ years. The market at 14% reflects a dramatic repricing from ~71% to 14% following the March 2026 mega-round, and with HIGH orderbook depth (8,329), this is a well-informed signal. My adjusted estimate of ~15% sits between the corrected binding constraint (18%) and the market (14%), reflecting that while an IPO is unlikely given the fresh $4B in capital and explicit leadership signals about patience, there remains a small but real chance of a confidential S-1 filing or surprise acceleration driven by investor liquidity pressure or IPO ratchet provisions we don't know about.